MX2017012999A - Acido pirrolidona carboxilico (pca) para uso oftalmico. - Google Patents

Acido pirrolidona carboxilico (pca) para uso oftalmico.

Info

Publication number
MX2017012999A
MX2017012999A MX2017012999A MX2017012999A MX2017012999A MX 2017012999 A MX2017012999 A MX 2017012999A MX 2017012999 A MX2017012999 A MX 2017012999A MX 2017012999 A MX2017012999 A MX 2017012999A MX 2017012999 A MX2017012999 A MX 2017012999A
Authority
MX
Mexico
Prior art keywords
pca
carboxylic acid
pyrrolidone carboxylic
ophthalmic use
disorders
Prior art date
Application number
MX2017012999A
Other languages
English (en)
Inventor
Baldacci Massimo
Original Assignee
Laboratori Baldacci Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratori Baldacci Spa filed Critical Laboratori Baldacci Spa
Publication of MX2017012999A publication Critical patent/MX2017012999A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a ácido pirrolidona carboxílico (PCA) y/o sus sales o derivados farmacéuticamente aceptables para uso en el tratamiento de enfermedades y/o trastornos oculares. Otro objeto de la presente invención son las composiciones que comprenden ácido pirrolidona carboxílico (PCA) y/o sus sales o derivados farmacéuticamente aceptables, al menos un excipiente fisiológicamente aceptable y opcionalmente al menos un ingrediente activo adicional para uso en el tratamiento de enfermedades y/o trastornos oculares.
MX2017012999A 2015-04-09 2016-04-06 Acido pirrolidona carboxilico (pca) para uso oftalmico. MX2017012999A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITUB20150226 2015-04-09
PCT/IB2016/051934 WO2016162795A1 (en) 2015-04-09 2016-04-06 Pyrrolidone carboxylic acid (pca) for ophthalmic use

Publications (1)

Publication Number Publication Date
MX2017012999A true MX2017012999A (es) 2018-05-22

Family

ID=53490161

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012999A MX2017012999A (es) 2015-04-09 2016-04-06 Acido pirrolidona carboxilico (pca) para uso oftalmico.

Country Status (14)

Country Link
US (2) US10272067B2 (es)
EP (1) EP3280412B1 (es)
CN (1) CN107530324A (es)
BR (1) BR112017021374A2 (es)
CA (1) CA2981444C (es)
ES (1) ES2754449T3 (es)
HU (1) HUE046056T2 (es)
LT (1) LT3280412T (es)
MX (1) MX2017012999A (es)
PL (1) PL3280412T3 (es)
PT (1) PT3280412T (es)
RU (1) RU2720993C2 (es)
UA (1) UA121329C2 (es)
WO (1) WO2016162795A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4324454A3 (en) * 2016-03-08 2024-05-01 University of Utah Research Foundation Cross-linking agents and associated methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2871060B1 (fr) * 2004-06-08 2008-07-11 Ajinomoto Kk Agent suppresseur pour l'inflammation et procede l'utilisant
EP1848541A4 (en) * 2005-02-07 2013-01-16 Pharmalight Inc METHOD AND DEVICE FOR OPHTHALMIC DELIVERY OF PHARMACEUTICALLY ACTIVE INGREDIENTS
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
US20070297981A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
EP1847536A1 (en) * 2006-04-20 2007-10-24 Prodimed, S.A. Synthesis and uses of pyroglutamic acid derivatives
GB2456528B (en) * 2008-01-16 2012-08-22 Pangaea Lab Ltd Antioxidant for use in cosmetic, medicated and pharmaceutical compositions
CN101698656B (zh) * 2009-11-05 2011-12-14 青岛成功精细化工有限公司 催化合成l-吡咯烷酮羧酸及其盐的方法
WO2012092375A1 (en) * 2010-12-29 2012-07-05 Inspire Pharmaceuticals, Inc. Method for treating dry eye
US8758836B2 (en) * 2011-09-09 2014-06-24 Nina S. YOSHPE Method and formulation for treating dry ear inflammation with cortisone
US9265782B2 (en) * 2013-02-22 2016-02-23 Ader Enterprises, Inc. Compositions, methods, and devices for the treatment of eye stain
KR101587412B1 (ko) * 2014-10-17 2016-01-21 주식회사 휴온스 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물

Also Published As

Publication number Publication date
US20180078527A1 (en) 2018-03-22
US20190216778A1 (en) 2019-07-18
US10272067B2 (en) 2019-04-30
WO2016162795A1 (en) 2016-10-13
EP3280412B1 (en) 2019-08-14
PT3280412T (pt) 2019-11-15
US10456374B2 (en) 2019-10-29
LT3280412T (lt) 2019-11-25
ES2754449T3 (es) 2020-04-17
CA2981444C (en) 2023-05-02
CA2981444A1 (en) 2016-10-13
HUE046056T2 (hu) 2020-01-28
RU2017135273A (ru) 2019-04-05
RU2720993C2 (ru) 2020-05-15
CN107530324A (zh) 2018-01-02
EP3280412A1 (en) 2018-02-14
UA121329C2 (uk) 2020-05-12
RU2017135273A3 (es) 2019-09-03
PL3280412T3 (pl) 2020-01-31
BR112017021374A2 (pt) 2018-07-03

Similar Documents

Publication Publication Date Title
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
PH12016501355A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
NZ735575A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP4374873A3 (en) Methods for treating or preventing opthalmological conditions
MY197845A (en) Pharmaceutical composition
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
MX2023003124A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
MX2018007511A (es) Compuestos de alquinil dihidroquinolina sulfonamida.
EP4364810A3 (en) Topical formulations and uses thereof
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
MX2017012999A (es) Acido pirrolidona carboxilico (pca) para uso oftalmico.
PH12019501785A1 (en) Intranasal composition comprising betahistine
EP3795170C0 (en) PHARMACEUTICAL COMPOSITION COMPRISING CCN5 USED AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF RETINAL DISEASE
WO2015162552A3 (en) Composition for topic use
MX2018012952A (es) Composicion oftalmica que comprende una combinacion sinergica de glucogeno y acido hialuronico o sal del mismo.
PH12016502527B1 (en) Stabilized desmopressin
UA97983U (uk) Лікарська композиція для лікування захворювань суглобів